The DOI matches its Crossref record.
International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group.
Abstract
PURPOSE: Cisplatin-containing chemotherapy has dramatically improved the outlook for patients with metastatic germ cell tumors (GCT), and overall cure rates now exceed 80%. To make appropriate risk-based decisions about therapy and to facilitate collaborative trials, a simple prognostic factor-based staging classification is required. MATERIALS: Collaborative groups from 10 countries provided clinical data on patients with metastatic GCT treated with cisplatin-containing chemotherapy. Multivariate analyses of prognostic factors for progression and survival were performed and models were validated on an independent data set. RESULTS: Data were available on 5,202 patients with nonseminomatous GCT (NSGCT) and 660 patients with seminoma. Median follow-up time was 5 years. For NSGCT the following independent adverse factors were identified: mediastinal primary site; degree of elevation of alpha-fetoprotein (AFP), human chorionic gonadotropin (HCG), and lactic dehydrogenase (LDH); and presence of nonpulmonary visceral metastases (NPVM), such as liver, bone, and brain. For seminoma, the predominant adverse feature was the presence of NPVM. Integration of these factors produced the following groupings: good prognosis, comprising 60% of GCT with a 91% (89% to 93%) 5-year survival rate; intermediate prognosis, comprising 26% of GCT with a 79% (75% to 83%) 5-year survival rate; and poor prognosis, comprising 14% of GCT (all with NSGCT) with a 48% (42% to 54%) 5-year survival rate. CONCLUSION: An easily applicable, clinically based, prognostic classification for GCT has been agreed on between all the major clinical trial groups who are presently active worldwide. This should be used in clinical practice and in the design and reporting of clinical trials to aid international collaboration and understanding.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Sturgeon, C. M., Duffy, M. J., Stenman, U.-H., Lilja, H., Brünner, N., Chan, D. W., Babaian, R., Bast, R. C., Dowell, B., Esteva, F. J., et al. (2008) · Clinical Chemistry · doi:10.1373/clinchem.2008.105601 · Cited by 1,129
Review of the Comparative Pharmacology and Clinical Activity of Cisplatin and Carboplatin
Go, R. S., & Adjei, A. A. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.1.409 · Cited by 697
Pedrazzoli, P., Ledermann, J. A., Lotz, J.-P., Leyvraz, S., Aglietta, M., Rosti, G., Champion, K. M., Secondino, S., Selle, F., Ketterer, N., et al. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl044 · Cited by 655
Krege, S., Beyer, J., Souchon, R., Albers, P., Albrecht, W., Algaba, F., Bamberg, M., Bodrogi, I., Bokemeyer, C., Cavallin-Ståhl, E., et al. (2008) · European Urology · doi:10.1016/j.eururo.2007.12.024 · Cited by 617
Cardiovascular Disease as a Long-Term Complication of Treatment for Testicular Cancer
Huddart, R. A., Norman, A., Shahidi, M., Horwich, A., Coward, D., Nicholls, J., & Dearnaley, D. P. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.173 · Cited by 547
Duwe, B. V., Sterman, D. H., & Musani, A. I. (2005) · Chest · doi:10.1378/chest.128.4.2893 · Cited by 534
Schmoll, H. J., Souchon, R., Krege, S., Albers, P., Beyer, J., Kollmannsberger, C., Fossa, S. D., Skakkebaek, N. E., de Wit, R., Fizazi, K., et al. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh301 · Cited by 510
Bokemeyer, C., Nichols, C. R., Droz, J.-P., Schmoll, H.-J., Horwich, A., Gerl, A., Fossa, S. D., Beyer, J., Pont, J., Kanz, L., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.07.062 · Cited by 503
High-Dose Chemotherapy and Stem-Cell Rescue for Metastatic Germ-Cell Tumors
Einhorn, L. H., Williams, S. D., Chamness, A., Brames, M. J., Perkins, S. M., & Abonour, R. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067749 · Cited by 496
Cheng, L., Albers, P., Berney, D. M., Feldman, D. R., Daugaard, G., Gilligan, T., & Looijenga, L. H. J. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0029-0 · Cited by 462
Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
Gilligan, T., Lin, D. W., Aggarwal, R., Chism, D., Cost, N., Derweesh, I. H., Emamekhoo, H., Feldman, D. R., Geynisman, D. M., Hancock, S. L., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0058 · Cited by 450
Horwich, A., Shipley, J., & Huddart, R. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68305-0 · Cited by 398
Rajpert-De Meyts, E., McGlynn, K. A., Okamoto, K., Jewett, M. A. S., & Bokemeyer, C. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00991-5 · Cited by 398
Curing metastatic testicular cancer
Einhorn, L. H. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.072067999 · Cited by 387
Motzer, R. J., Nichols, C. J., Margolin, K. A., Bacik, J., Richardson, P. G., Vogelzang, N. J., Bajorin, D. F., Lara, P. N., Einhorn, L., Mazumdar, M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.4528 · Cited by 353
Testicular Cancer — Discoveries and Updates
Hanna, N. H., & Einhorn, L. H. (2014) · New England Journal of Medicine · doi:10.1056/nejmra1407550 · Cited by 345
Büchner, T., Berdel, W. E., Haferlach, C., Haferlach, T., Schnittger, S., Müller-Tidow, C., Braess, J., Spiekermann, K., Kienast, J., Staib, P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.4245 · Cited by 338
ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up
Honecker, F., Aparicio, J., Berney, D., Beyer, J., Bokemeyer, C., Cathomas, R., Clarke, N., Cohn-Cedermark, G., Daugaard, G., Dieckmann, K.-P., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy217 · Cited by 326
Petrelli, F., Cabiddu, M., Coinu, A., Borgonovo, K., Ghilardi, M., Lonati, V., & Barni, S. (2015) · Acta Oncologica · doi:10.3109/0284186x.2015.1043026 · Cited by 323
The International Prognostic Factors Study Group (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.8128 · Cited by 322
Beyer, J., Albers, P., Altena, R., Aparicio, J., Bokemeyer, C., Busch, J., Cathomas, R., Cavallin-Stahl, E., Clarke, N. W., Claßen, J., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mds579 · Cited by 320
Guidelines on Testicular Cancer
Albers, P., Albrecht, W., Algaba, F., Bokemeyer, C., Cohn-Cedermark, G., Horwich, A., Klepp, O., Laguna, M. P., & Pizzocaro, G. (2005) · European Urology · doi:10.1016/j.eururo.2005.06.019 · Cited by 314
Gilligan, T. D., Seidenfeld, J., Basch, E. M., Einhorn, L. H., Fancher, T., Smith, D. C., Stephenson, A. J., Vaughn, D. J., Cosby, R., & Hayes, D. F. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.4481 · Cited by 297
Ding, J., Karp, J. E., & Emadi, A. (2017) · Cancer Biomarkers · doi:10.3233/cbm-160336 · Cited by 287
Oldenburg, J., Fosså, S. D., Nuver, J., Heidenreich, A., Schmoll, H.-J., Bokemeyer, C., Horwich, A., Beyer, J., & Kataja, V. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt304 · Cited by 282
Davis, F. G., Dolecek, T. A., McCarthy, B. J., & Villano, J. L. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos152 · Cited by 256
Cierna, Z., Mego, M., Miskovska, V., Machalekova, K., Chovanec, M., Svetlovska, D., Hainova, K., Rejlekova, K., Macak, D., Spanik, S., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdv574 · Cited by 162
Systemic immune-inflammation index in germ-cell tumours
Chovanec, M., Cierna, Z., Miskovska, V., Machalekova, K., Kalavska, K., Rejlekova, K., Svetlovska, D., Macak, D., Spanik, S., Kajo, K., et al. (2018) · British Journal of Cancer · doi:10.1038/bjc.2017.460 · Cited by 90
Fankhauser, C. D., Sander, S., Roth, L., Gross, O., Eberli, D., Sulser, T., Seifert, B., Beyer, J., & Hermanns, T. (2018) · British Journal of Cancer · doi:10.1038/bjc.2017.467 · Cited by 80
Chovanec, M., Cierna, Z., Miskovska, V., Machalekova, K., Svetlovska, D., Kalavska, K., Rejlekova, K., Spanik, S., Kajo, K., Babal, P., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15585 · Cited by 79
De Giorgi, U., Demirer, T., Wandt, H., Taverna, C., Siegert, W., Bornhauser, M., Kozak, T., Papiani, G., Ballardini, M., & Rosti, G. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi017 · Cited by 69
Lobo, J., Rodrigues, Â., Guimarães, R., Cantante, M., Lopes, P., Maurício, J., Oliveira, J., Jerónimo, C., & Henrique, R. (2019) · Cancers · doi:10.3390/cancers11101535 · Cited by 69
Albany, C., Einhorn, L., Garbo, L., Boyd, T., Josephson, N., & Feldman, D. R. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0544 · Cited by 51
Secondary malignant neoplasms in testicular cancer survivors
Curreri, S. A., Fung, C., & Beard, C. J. (2015) · Urologic Oncology: Seminars and Original Investigations · doi:10.1016/j.urolonc.2015.05.002 · Cited by 44
Jennewein, L., Bartsch, G., Gust, K., Kvasnicka, H., Haferkamp, A., Blaheta, R., Mittelbronn, M., Harter, P., & Mani, J. (2018) · Oncology Letters · doi:10.3892/ol.2018.8597 · Cited by 27
Loh, K. P., & Fung, C. (2017) · Rare Tumors · doi:10.4081/rt.2017.6867 · Cited by 23
Pęksa, R., Kunc, M., Popęda, M., Piątek, M., Bieńkowski, M., Żok, J., Starzyńska, A., Perdyan, A., Sowa, M., Duchnowska, R., et al. (2021) · Cancers · doi:10.3390/cancers13081750 · Cited by 16
The Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Metastatic Testicular Cancer
Ribnikar, D., Stukalin, I., Bedard, P. L., Hamilton, R. J., Jewett, M., Warde, P., Chung, P., Anson-Cartwright, L., Templeton, A. J., Amir, E., et al. (2020) · Current Oncology · doi:10.3390/curroncol28010014 · Cited by 15
Metadata
- Venue
- Journal of Clinical Oncology
- Published
- 1997-02
- Volume
- 15
- Issue
- 2
- Pages
- 594-603
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W44254208
- Cited by
- 1,929
- References
- 0
- FWCI
- 34.46
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.